CreatorsPublishersAdvertisers
View more in
Diseases & Treatments

The promising effects of an α-synuclein targeted immunotherapy in treating early Parkinson's disease

Stamford Advocate
 2021-09-14

Cover picture for the articleMILWAUKEE (PRWEB) September 14, 2021. Patients with early Parkinson’s disease (PD) who were treated for two years with prasinezumab, an α-synuclein targeted immunotherapy, saw more favorable motor progression scores than those who received delayed-start treatment with prasinezumab, according to a study being presented at the MDS Virtual Congress 2021. Aggregation...

www.stamfordadvocate.com

Comments / 0

Comments / 0